U.S. Court of Appeals for the Federal Circuit
Sanofi-Aventis U.S., LLC v. Fresenius Kabi USA, LLC
This writing
- Type
- Opinion
- Filed
- Aug. 14, 2019
- Case
- Sanofi-Aventis U.S., LLC v. Fresenius Kabi USA, LLC
- Case status
- Decided
Source No authoring judge could be established for this writing, either from provider metadata or from the signature line of the court's published opinion. Benchlight shows the gap rather than guessing at an author.
Opening text
The first passage of the document, as extracted by the source provider.
Lourie, Circuit Judge. Plaintiffs-Appellants (collectively, "Sanofi") appeal from the judgment of the U.S. District Court for the District of New Jersey holding, after a bench trial, claims 7, 11, 14-16, and 26 of U.S. Patent 8,927,592 (the " '592 patent") invalid as obvious. Sanofi-Aventis U.S. LLC v. Fresenius Kabi USA, LLC , No. 14-7869 (D.N.J. Dec. 19, 2017) ("…
Source Extract supplied by CourtListener. Benchlight does not host the document — read the authoritative text in the court's own PDF.